EraCal Therapeutics AG

Excess weight and obesity are among the most widespread health risks globally. EraCal fights it: the University of Zurich and Harvard University spin-off, founded in 2018, develops a novel drug candidate Era-379 to reduce appetite. Reducing appetite facilitates blood sugar and lipid control, reduces body weight and liver fat content, and facilitates healthy aging thereby EraCal pioneers the next generation of cardiometabolic therapies.